Fig. 3

Cell size normalizes already after 1 week of ruxolitinib treatment, but migration and receptor expressions remain unaffected. a Statistical summary of percentage of moving cells (top) and speed excluding non-moving cells (speed excl. Nmc., bottom), of purified aCML neutrophils after 1 week of treatment with ruxolitinib (black triangles, grey bars; n = 1), compared to the healthy age- and gender-matched controls (black dots, white bars; n = 6). Each symbol represents a single individual. Bars are given as median ± interquartile range. (B) The first frame of image sequences acquired during video microscopy of neutrophils of the aCML patient after 1 week of ruxolitinib therapy. From left to right, the cells were treated with PBS as a control, fMLP [10 nM], CXCL1 [100 ng/ml] and CXCL8 [100 ng/ml]. Magnification: 20x. c Statistical summary of the cell size in μm² of aCML neutrophils (black triangles, grey bars) after 1 week of ruxolitinib treatment (top) and the relative number of neutrophils with a cell size of > 225 μm² (bottom). Both parameters were compared to age- and gender-matched controls (black dots, white bars; n = 6). On average, 41 and 56 cells per condition were analyzed in age- and gender-matched controls and the aCML patient, respectively. Bars are given as median ± interquartile range and the given p-values were calculated using Mann-Whitney U test. The cutoff of 225 μm² (top) is displayed as a dashed grey line. d Statistical summary of expression levels for CD16, CD15, fMLPR, CXCR1 and CXCR2 on purified neutrophils from age-matched controls (controls; black dots, white bars; n = 5) and aCML neutrophils after 1 week of ruxolitinib treatment (1 week; black triangles, grey bars; n = 1). Expression levels are given as the mean fluorescent intensity (mfi). Bars are given as median ± interquartile range